Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Effects of Early Cell Damage from Repetitive Intermittent Fever Exposure in Alopecia Progression and Evaluation of New Candidate Drugs: Ibuprofen, Menthol, and Cetirizine

간헐적 발열 반응에 의한 세포 손상과 이와 관련된 탈모 치료를 위한 신 후보물질 연구

  • Lim, Sung Cil (College of Pharmacy, The Catholic University of Korea) ;
  • Moon, Hong Seop (College of Pharmacy and Natural Medicine Research Institute, Mokpo National University)
  • 임성실 (가톨릭대학교 약학대학) ;
  • 문홍섭 (국립목포대학교 약학대학 천연약물연구소)
  • Received : 2016.06.22
  • Accepted : 2016.09.06
  • Published : 2016.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Alopecia areata (AA) is a very disturbing and expensive disorder in which the exact etiology is not known and it is yet to be treated completely well. Most alopecia patients exhibit some inflammation in the hair follicles regardless of the causes. The clinical symptoms of alopecia present very diversely while the prime symptom is local intermittent fever which are related to inflamed cells. Methods: This study aimed to evaluate how repetitive intermittent fever can damage the normal human dermal fibroblast (NHDF) cells and investigated the cytotoxic and proliferative effects after application of new candidate drugs (ibuprofen, menthol, cetirizine) for alopecia in comparison to minoxidil. Results: This study demonstrated that ibuprofen, menthol, or/and cetirizine can prevent or slow down the damage of NHDF cells from intermittent fever in early alopecia. Aggressive preventative intervention with those drugs before complete destruction of hair follicle by excessive repetitive fever, is a very important step for alopecia therapy and these drugs are recommended as candidate drugs for alopecia in the future. Conclusion: Aggressive preventative intervention with drugs before complete destruction of hair follicles (NHDF cells) by excessive repetitive fever is a very important step for alopecia therapy or progression.

Keywords

References

  1. Choi GS. Hair characteristics and androgenetic alopecia in Koreans. J Korean Med 2013;56:45-54.
  2. Valente Duarte de Sousa IC, Tosti A. New investigational drugs for androgenetic alopecia. Expert Opin Investig Drugs 2013;22:573-89. https://doi.org/10.1517/13543784.2013.784743
  3. Han JH, Kwon OS, Chung JH, et al. Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicle. J Dermatol Sci 2004;34(2):91-8. https://doi.org/10.1016/j.jdermsci.2004.01.002
  4. Kwon OE, Ku BS, Lee YK, et al. Histopathologic gradings correlate with clinical prognostic factors and therapeutic effects in patient with alopecia areata. Korean J Dermatol 2007;45(2):111-8.
  5. Giustizieri ML, Albanesi C, Fluhr J, et al. H1 histamine receptor mediated inflammatory responses in human keratinocytes. J Allergy Clin Immunol 2004;114(5):1176-82. https://doi.org/10.1016/j.jaci.2004.07.054
  6. Smith A, Trueb R M, Theiler M, et al. High relapse rates despite early intervention with intravenous methylprednisolone pulse therapy for severe childhood alopecia areata. Pediatr Dermatol 2015;32:481. https://doi.org/10.1111/pde.12578
  7. Randall VA. Androgens and hair growth. Dermatol Ther 2008;21(5):314-28. https://doi.org/10.1111/j.1529-8019.2008.00214.x
  8. Ligia B, Beata B, Dominika W, et al. New aspects of the treatment of alopecia areata. Postepy Dermatol Alergol 2014;31:262-5.
  9. Messenger AG, Mckillop J, Farrant P, et al. British association of Dermatologists' guidelines for the management of alopecia areata 2012. Br J Dermatol 2012;166(5):916-26. https://doi.org/10.1111/j.1365-2133.2012.10955.x
  10. Inui S, Nakajima T, Toda N, et al. Fexofenadine hydrochloride enhances the efficacy of contact immunotherapy for extensive alopecia areata: Retrospective analysis of 121 cases. J Dermatol 2009;36(6):323-7. https://doi.org/10.1111/j.1346-8138.2009.00647.x
  11. Ito T. Advances in the management of alopecia areata. J Dermatol 2012;39(1):11-7. https://doi.org/10.1111/j.1346-8138.2011.01476.x
  12. Santos Z, Avci P, Hamblin M R. Drug Discovery for alopecia: gone today, hair tomorrow. Expert Opin Drug Discov 2015;10(3):269-92. https://doi.org/10.1517/17460441.2015.1009892
  13. Biran R, Zlotogorski A, Ramot Y. The genetics of alopecia areata: New approaches, new findings, new treatments. J Dermatol Sci 2015;78(1):11-20. https://doi.org/10.1016/j.jdermsci.2015.01.004
  14. Poqatzki-Zahn E, Marziniak M, Schneider G, et al. Chronic pruritus:targets, mechanisms and therapies. Drug News Perspect 2008;21(10):541. https://doi.org/10.1358/dnp.2008.21.10.1314057
  15. Leslie TA, Greaves, M.W, Yosiporitch, G. Current topical and systemic therapies for itch. Handb Exp Pharmacol 2015;226:337-56.
  16. Metz M, Grundmann S, Stander S. Pruritus: an overview of current concepts. Vet Dermatol 2011;22(2):121-31. https://doi.org/10.1111/j.1365-3164.2010.00945.x
  17. Freyscjmodt-Paul P, Happle R, Hoffman R. Alopecia areata in animal models-new insights into pathogenesis and treatment of a T cell-medicated autoimmune disorder. J Dtsch Drmatol Ges 2004;2(4):260-73. https://doi.org/10.1046/j.1610-0387.2003.03553.x-i1
  18. Schumacher S, Kietzmann M, Stark H, et al. Unique immunomodulatory effects of azelastine on dendritic cells in vitro. Naunyn Schmiedebergs Arch Pharmacol 2014;387(11):1091-9. https://doi.org/10.1007/s00210-014-1033-x
  19. Alkhalifah A, Alsantali A, Wang E, et al. Alopecia areata update Part II. treatment. J Am Acad Dermatol 2010;62(2):191-202. https://doi.org/10.1016/j.jaad.2009.10.031
  20. American Hair Loss Association. Available from www.amercianhariloss.org. Accessed April 2, 2016
  21. Korean Society Hair Restoration Treatment. Available from www.kshrt.or.kr. Accessed April 2, 2016
  22. Korean Dermatological Association. Available from www.derma.or.kr. Accessed April 2, 2016
  23. Totoda M, Makino T, Kagoura M, et al. Expression of neuropeptidedegrading enzymes in alopecia areata: an immunohistochemical study. Br J Dermatol 2001;144(1):46-54. https://doi.org/10.1046/j.1365-2133.2001.03951.x